Anthropic announced on October 27, 2026, a drug discovery partnership with Bristol-Myers Squibb and its acquisition of Mithril Medicine, a biotech founded by one person. The founder used Claude and part-time consultants to take a muscular dystrophy antibody from concept to mouse proof of principle in 18 months, and Anthropic says it could be trial-ready by the end of 2028. The discussion has since widened: the 326-page IPO paperwork uses the word reputation 103 times, and disclosed acquisitions total about $737 million excluding Coefficient Bio, with roughly $260 million undisclosed. Whether the deal is validation or marketing ahead of the listing remains contested.